RAPT
RAPT Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$58.01
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +4.9%
- EBIT
- +1.9%
- EPS
- +50.2%
- Free cash flow
- +14.0%
- Operating cash flow
- +13.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -7.2%
- EBIT
- -7.1%
- Net income
- -11.2%
- EPS
- -4.6%
- Free cash flow
- +15.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025